Skip to main content
CF PharmTech, Inc. logo

CF PharmTech, Inc. — Investor Relations & Filings

Ticker · 2652 HKEX Manufacturing
Open in API
Filings indexed 80 across all filing types
Latest filing 2026-04-01 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 2652

About CF PharmTech, Inc.

https://www.cfpharmtech.com

CF PharmTech, Inc. is a commercial-stage specialty pharmaceutical company specializing in the research, development, manufacturing, and commercialization of complex drug delivery systems, primarily focusing on inhalation technologies. The company develops treatments for major respiratory conditions, including asthma, Chronic Obstructive Pulmonary Disease (COPD), and allergic rhinitis. Its core product platforms encompass Inhalation Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), inhalation liquid preparations (nebulizers), and nasal sprays. The firm also leverages advanced formulation techniques, such as liposomes, to enhance drug efficacy and delivery.

Recent filings

Filing Released Lang Actions
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a ‘‘Next Day Disclosure Return’’ (Form FF305) filed under the HKEX Listing Rules, detailing changes in issued shares and treasury shares including a share repurchase on 1 April 2026. It is not an announcement of a separate report but the actual regulatory disclosure of the company’s transactions in its own shares. This aligns precisely with the “Transaction in Own Shares” category (POS).
2026-04-01 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a detailed HKEX “Next Day Disclosure Return” form FF305 covering changes in issued shares and treasury shares including share repurchases (buybacks) under Main Board and GEM Rules. It provides transaction details, repurchase prices, volumes, and confirmations—fully matching the “Transaction in Own Shares (POS)” category for share repurchase/issuance reports rather than a brief announcement or other filing type.
2026-03-31 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Earnings Release Classification · 1% confidence The document is titled “Annual Results Announcement for the Year Ended December 31, 2025” and contains a preliminary announcement of full‐year financial results under the Hong Kong Listing Rules, including key financial highlights and Management Discussion & Analysis. It is not the full statutory annual report but a concise earnings release covering the period’s performance. Therefore, it fits the “Earnings Release (ER)” category. FY 2025
2026-03-30 English
VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION WITH JD HEALTH
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement filed on the Hong Kong Exchange, detailing a strategic cooperation agreement with JD Health. It does not report financial results (so not ER or IR), it is not a results transcript (CT), not management/downstream report (MDA), not an offering or financing update (CAP), nor does it relate to board changes, dividends, share transactions, mergers or acquisitions, audit, ESG or governance frameworks. It is essentially a general regulatory announcement of a business cooperation, which falls under the fallback “Regulatory Filings” category (RNS).
2026-03-23 English
INSIDE INFORMATION PROFIT WARNING
Earnings Release Classification · 1% confidence The document is an 'Inside Information Profit Warning' issued by CF PharmTech, Inc. It provides a preliminary assessment of the company's financial performance for the year 2025, highlighting expected decreases in revenue and net profit compared to 2024. It explains the reasons for these changes (e.g., VBP arrangements, market demand, R&D costs) and provides non-IFRS financial measures. This type of announcement is a standard regulatory disclosure required by the Hong Kong Stock Exchange (HKEX) when a company anticipates a significant change in financial results before the formal annual report is published. It fits the definition of an 'Earnings Release' (ER) as it is an initial announcement of financial results/highlights, rather than the full annual report itself. FY 2025
2026-03-20 English
VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF IND APPLICATION FOR ICF001 BY THE NMPA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by CF PharmTech, Inc. regarding the acceptance of an Investigational New Drug (IND) application by the NMPA for a specific product (ICF001). It details the product, its strategic significance, and associated risks. Since this is a regulatory announcement regarding company operations and R&D progress that does not fit into specific categories like financial reports, dividends, or board changes, it falls under the 'Regulatory Filings' (RNS) category.
2026-03-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.